Treatments for Acute Myeloid Leukemia

 Treatments for Acute Myeloid Leukemia

Drugs used to treat Acute Myeloid Leukemia

olutasidenib

Idamycin PFS

glasdegib

cytarabine liposomal / daunorubicin liposomal

ivosidenib

midostaurin

gemtuzumab

Daurismo

gilteritinib

enasidenib

Vyxeos

Onureg

Mylotarg

daunorubicin

Xospata

vincristine

Rydapt

idarubicin

decitabine

Tibsovo

Idhifa

azacitidine

venetoclax

Venclexta

cytarabine

Vanflyta

Rezlidhia

quizartinib

 

What is Acute Myeloid Leukemia?

 

Acute Myeloid Leukemia (AML) is a type of cancer that starts in the bone marrow—the soft inner parts of certain bones where new blood cells are made—and often quickly moves into the blood. It can spread to other parts of the body, including the lymph nodes, liver, spleen, and central nervous system. Here’s a detailed look into AML, including its causes, symptoms, diagnosis, and treatment options.

 

1. What is AML?

 

AML is characterized by the rapid proliferation of abnormal myeloid cells, which are immature white blood cells, known as blasts. These cells crowd out healthy blood cells, impairing the body’s ability to fight infection, carry oxygen, and prevent bleeding.

 

AML is called "acute" because it tends to progress quickly, often within weeks, compared to chronic types of leukemia, which progress more slowly. It is most common in adults but can occur in children as well.

 

2. Types of AML

 

AML is classified based on various factors, including:

   - Genetic Mutations: AML can be categorized based on certain genetic changes, which impact prognosis and treatment plans.

   - Lineage: Subtypes are defined based on which types of cells are primarily involved (e.g., myeloblasts, monocytes).

   - WHO Classification: The World Health Organization classifies AML into multiple subtypes based on chromosomal abnormalities, gene mutations, and other factors.

 

Common AML subtypes include:

   - Acute Promyelocytic Leukemia (APL): This is a unique subtype with specific treatment protocols.

   - AML with mutated NPM1 or FLT3: These gene mutations affect treatment choices.

   - Therapy-related AML: Develops as a result of prior chemotherapy or radiation therapy for other cancers.

 

3. Causes and Risk Factors

 

While the exact cause of AML is unknown, several risk factors can increase the likelihood of developing AML:

   - Age: AML is more common in older adults, particularly those over 65.

   - Genetic Disorders: Conditions like Down syndrome, Fanconi anemia, and other inherited bone marrow failure syndromes are associated with a higher risk of AML.

   - Previous Cancer Treatments: Certain chemotherapy drugs and radiation therapy increase the risk of developing AML.

   - Exposure to Chemicals: Prolonged exposure to benzene (found in gasoline, certain industrial settings) is linked to a higher risk.

   - Smoking: Increases risk due to exposure to benzene and other carcinogens.

 

4. Symptoms of AML

 

AML symptoms can appear suddenly and worsen quickly due to the rapid buildup of abnormal cells. Common symptoms include:

   - Fatigue and Weakness: Due to anemia from reduced red blood cell counts.

   - Frequent Infections: Due to reduced white blood cells that fight infection.

   - Bruising or Bleeding Easily: Low platelet counts cause easy bruising, bleeding gums, or frequent nosebleeds.

   - Bone Pain: Caused by overcrowding of cells in the bone marrow.

   - Swollen Lymph Nodes, Liver, or Spleen: Due to infiltration by leukemia cells.

   - Shortness of Breath: Especially during physical activity, due to anemia.

   - Fever and Night Sweats: Sometimes related to infection or cancer itself.

 

5. Diagnosis of AML

 

Diagnosis is confirmed through several tests:

   - Blood Tests: A complete blood count (CBC) can reveal low red blood cells, white blood cells, and platelets.

   - Bone Marrow Biopsy: A sample of bone marrow is taken from the hip bone to look for leukemia cells.

   - Cytogenetics and Molecular Testing: Tests for specific chromosomal changes or mutations in genes like FLT3, NPM1, and CEBPA, which can guide treatment.

   - Flow Cytometry: Helps classify AML by analyzing the proteins on leukemia cells.

   - Imaging Tests: To check for spread, especially if there are symptoms affecting specific organs.

 

6. Treatment Options for AML

 

AML treatment often depends on the patient’s age, health, AML subtype, and the presence of certain genetic mutations.

 

Standard Treatments

   - Induction Chemotherapy: The goal is to achieve remission by killing as many leukemia cells as possible. Common drugs include cytarabine and anthracyclines like daunorubicin or idarubicin.

   - Consolidation Therapy: After remission, further chemotherapy (or a stem cell transplant) is given to prevent relapse.

   - Stem Cell Transplant (SCT): For patients who achieve remission, a stem cell transplant (allogeneic) may be recommended to replace the diseased bone marrow with healthy cells from a donor.

   - Targeted Therapy: Drugs like midostaurin, gilteritinib, and venetoclax target specific mutations or cell pathways. These drugs are used in patients with mutations in genes such as FLT3 or IDH.

   - Acute Promyelocytic Leukemia (APL) Treatment: This subtype is treated with targeted therapy using all-trans retinoic acid (ATRA) and arsenic trioxide.

 

Experimental and Supportive Treatments

   - Clinical Trials: New drugs, CAR T-cell therapy, or novel targeted agents may be available through clinical trials.

   - Supportive Care: Includes blood transfusions, antibiotics, and medications to prevent or manage side effects.

 

7. Prognosis and Survival Rates

 

Prognosis in AML depends on several factors:

   - Age: Younger patients have better outcomes.

   - Cytogenetics and Genetic Mutations: Patients with certain genetic mutations, like FLT3, tend to have more aggressive forms of AML, affecting prognosis.

   - AML Subtype: APL has a unique treatment and often a favorable prognosis if treated properly.

   - Response to Initial Treatment: Achieving remission with induction therapy improves outcomes.

 

The 5-year survival rate varies widely based on these factors but is around 25-30% for adults overall, though higher in younger patients.

 

8. Lifestyle and Follow-Up

 

After treatment, patients are advised to:

   - Attend Regular Follow-Up Appointments: Regular monitoring is essential to detect recurrence.

   - Manage Long-Term Side Effects: Treatments can have lasting impacts on organs, bone density, and mental health.

   - Adopt a Healthy Lifestyle: Includes a balanced diet, physical activity, and avoiding tobacco and alcohol, which helps in recovery.

 

9. Recent Advances and Research in AML

 

New therapies and research are focusing on:

   - Immunotherapies: CAR T-cell therapies and immune checkpoint inhibitors are under investigation for AML.

   - Personalized Medicine: Genetic profiling of AML is helping tailor treatments for better outcomes.

   - New Targeted Drugs: Ongoing studies focus on drugs that target specific mutations in AML, aiming for higher efficacy and fewer side effects.

 

AML remains one of the more challenging cancers to treat due to its aggressive nature, but advances in genetics, targeted therapies, and supportive care have improved outcomes and quality of life for many patients.